Latest Viking Therapeutics News & Updates

See the latest news and media coverage for Viking Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Viking Therapeutics

Clinical-stage biotechnology company

vikingtherapeutics.com

Headquarters: San Diego, United States
Founded year: 2012
Company type: Public company
Number of employees: 60–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Viking Therapeutics

In short: Viking Therapeutics advanced its obesity drug pipeline, launching a $500M shelf offering following Phase 3 enrollment milestones.

Company announcements

July 23 Viking Therapeutics

Viking Therapeutics appoints Dorothy Gemmell to Board of Directors

She held executive roles at GoodRx, Capsule, and Havas Life, with experience in commercialization.

July 22 Viking Therapeutics

Viking Therapeutics reports Q2 2026 financial results and update

Phase 3 VANQUISH trials for VK2735 in obesity are fully enrolled, and the company maintains a strong cash position of $502 million.

June 24 Viking Therapeutics

Viking Therapeutics initiates Phase 1 study of VK3019 in healthy adults

The trial evaluates safety, tolerability, and pharmacokinetics of the novel amylin receptor agonist for weight loss.

April 29 Viking Therapeutics

Viking Therapeutics reports Q1 2026 financial results

VANQUISH-1 and -2 trials fully enrolled. Oral VK2735 Phase 3 starts 4Q26. Cash at $603M. Net loss $158.3M.

Media coverage

July 30 Yahoo Finance

VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’

Viking Therapeutics said the proceeds would be used to support the continued development and...

July 30 The Globe and Mail

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

July 30 Yahoo Finance

VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress

Viking has no approved drug products, and in the pre-revenue phase, investor attention centers...

July 29 Seeking Alpha

Viking expects oral VK2735 Phase III start in fourth quarter as VANQUISH targets 78-week dosing

Lian said oral VK2735 Phase III is expected to start in Q4 and that Viking believes “VK2735 is positioned to become the first oral formulation...

Never miss news about Viking Therapeutics

Track Viking Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Viking Therapeutics competitors & trending companies

Browse news for competitors to Viking Therapeutics and other trending companies.